# Carcinoembryonic Antigen Market

> Carcinoembryonic Antigen Market Research Report Information by Application (Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, and Others), End User (Hospitals and Clinics, Diagnostic Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.68%
- **2025:** USD 2.32 Billion
- **2035:** USD 4.42 Billion
- **Key Players:** Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher (Beckman Coulter), Thermo Fisher Scientific, Fujirebio (H.U. Group), bioMérieux, Sysmex Corporation

**Report ID:** MRFR/Pharma/0288-HCR · **Pages:** 81 · **Author:** Rahul Gotadki & Satyendra Maurya · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/carcinoembryonic-antigen-market-772

---

## Market Summary

## Carcinoembryonic Antigen Market Summary

The Carcinoembryonic Antigen Market reached USD 2.32 Billion in 2025 and opens the forecast window at USD 2.47 Billion in 2026, climbing to USD 4.42 Billion by 2035 at a 6.68% CAGR. Two catalysts anchor that trajectory. The European Union's Council Recommendation on cancer screening, adopted in December 2022, pushed member states toward covering 90% of eligible populations for colorectal screening by 2025 [[1]](https://consilium.europa.eu). Across the Pacific, China's Healthy China 2030 oncology programme has directed roughly CNY 12 billion into county-level diagnostic infrastructure since 2021 [[2]](https://nhc.gov.cn), pulling immunoassay volumes into tier-3 and tier-4 hospitals for the first time.

Laboratories are retiring manual ELISA plate workflows in favour of automated chemiluminescent and electrochemiluminescent platforms that deliver a colorectal cancer biomarker result in under 20 minutes. Roche, Abbott and Siemens Healthineers collectively committed more than USD 4.1 billion to diagnostics R&D in FY2024 [[3]](https://roche.com)[[4]](https://abbott.com)[[5]](https://siemens-healthineers.com), much of it aimed at multiplex panels that run CEA alongside CA 19-9 and AFP on a single sample draw.

North America holds 38.9% of the Carcinoembryonic Antigen Market, supported by dense reimbursement coverage for post-resection surveillance. Asia-Pacific compounds fastest at 7.30% through 2035. Europe, second at USD 0.64 Billion in 2025, benefits from IVDR-driven consolidation onto validated platforms. Momentum now depends less on discovery than on distribution economics.

## Key Report Takeaways

### • By Product

- Assay kits commanded 42.4% of the Carcinoembryonic Antigen Market in 2025, sustained by recurring reagent consumption
- Consumables and reagents advance at a 7.71% CAGR through 2035 as installed analyzer bases mature

### • By Application

- Colorectal cancer accounted for 40.9% of application demand in 2025
- [Liver cancer](https://www.marketresearchfuture.com/reports/liver-cancer-market-26244) testing grows at 7.56% CAGR, the fastest application within the Carcinoembryonic Antigen Market
- Lung cancer applications represented USD 0.41 Billion in 2025

### • By End User

- Hospitals and surgical centres held a 45.8% share in 2025
- Diagnostic laboratories post a 7.44% CAGR, the strongest end-user trajectory

### • By Region

- North America led the Carcinoembryonic Antigen Market with 38.9% share in 2025
- Asia-Pacific expands at 7.30% CAGR to 2035
- Middle East & Africa contributed USD 0.10 Billion in 2025

## Market Size and Forecast (2021–2035)

Estimates blend bottom-up test-volume modelling from national cancer registries with top-down triangulation against diagnostics-segment revenue disclosures from twelve listed manufacturers. Reagent pull-through per installed analyzer was cross-checked against hospital procurement tenders in eight countries.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising colorectal cancer incidence | 1.6 | Global | Long-term (≥4 yr) | [6] |
| National screening programme expansion | 1.4 | Europe, Asia-Pacific | Medium-term (2–4 yr) | [1][2] |
| Automation of laboratory immunoassay workflows | 1.1 | North America, Europe | Medium-term (2–4 yr) | [3] |
| Post-surgical surveillance protocol adherence | 0.9 | North America | Short-term (≤2 yr) | [9] |
| Multiplex panel bundling economics | 0.8 | Global | Long-term (≥4 yr) | [4] |
| Emerging-market laboratory capacity build-out | 0.7 | Asia-Pacific, MEA | Long-term (≥4 yr) | [8][10] |
| Reimbursement clarity for surveillance testing | 0.5 | North America, Europe | Short-term (≤2 yr) | [11] |

### Rising Colorectal Cancer Incidence

In 2022, GLOBOCAN reported 1.93 million new cases of colorectal cancer globally, with the prevalence among persons under 50 increasing by almost 2% per year in twenty high-income nations [[6]](https://gco.iarc.fr). Over the course of a five-year surveillance period, each diagnosed patient produces six to twelve serial measurements. The base scenario for the carcinoembryonic antigen market is driven by volume rather than pricing.

### National Screening Programme Expansion

A EUR 4 billion EU4Health funding was included in Europe's screening recommendation through 2027 [[1]](https://consilium.europa.eu). Since 2023, organized fecal immunochemical test programs have been implemented in Poland, Romania, and Bulgaria. Positive results go straight into colonoscopy pathways, where baseline antigen assessment is a normal procedure prior to resection.

### Laboratory Automation

Beckman Coulter's DxI 9000 and Roche's cobas pro platforms process upward of 400 immunoassay tests per hour, cutting per-result labour cost by an estimated 34% against semi-automated predecessors [[3]](https://roche.com)[[12]](https://danaher.com). Consolidation onto fewer, faster analyzers has shifted procurement conversations from instrument price toward ten-year reagent commitments.

### Surveillance Protocol Adherence

NCCN guidelines recommend measurement every three to six months for two years after curative resection of stage II–III disease [[9]](https://nccn.org). Audit data from US integrated delivery networks show adherence improved from 61% to 74% between 2021 and 2024, largely through electronic health record order sets that auto-populate surveillance panels.

## Restraints

## Restraints Impact Analysis

Restraint weightings represent estimated drag on growth momentum within the Carcinoembryonic Antigen Market. They are directional analyst judgements rather than subtractive inputs to the compound rate.

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Low specificity limiting screening use | -1.2 | Global | Long-term (≥4 yr) | [9] |
| Reagent commoditisation and price erosion | -0.9 | North America, Europe | Medium-term (2–4 yr) | [13] |
| Inter-assay standardisation gaps | -0.7 | Global | Medium-term (2–4 yr) | [14] |
| IVDR compliance cost for smaller manufacturers | -0.5 | Europe | Short-term (≤2 yr) | [7] |
| Competition from circulating tumour DNA panels | -0.4 | North America | Long-term (≥4 yr) | [15] |

### Specificity Ceiling

Smokers, people with cirrhosis, and people with inflammatory bowel disease all have elevated readings, which can result in false-positive rates of 15–20% in groups without symptoms [[9]](https://nccn.org). The use of standalone screening, which limits the addressable population to diagnostic and post-treatment cohorts rather than the total adult population, is not supported by any significant guideline organization.

### Price Erosion

In open-channel economies like Brazil and India, third-party reagent makers now undercut branded kits by 30–45% [[13]](https://who.int). Even as unit volumes increased, tender awards in Brazil's SUS network in 2024 cleared at prices that were around 22% lower than those in 2021, reducing profitability.

### Standardisation Gaps

Results from different platforms diverge by 15–25% because calibration traces to non-harmonised reference materials [[14]](https://ifcc.org). IFCC harmonisation work remains incomplete, forcing clinicians to keep patients on a single assay throughout surveillance and dampening competitive switching within the Carcinoembryonic Antigen Market.

## Opportunities

## Carcinoembryonic Antigen Market Opportunities

### Near-Patient Cartridge Systems

Oncology day-care units want same-visit results. Cartridge platforms delivering readings in 12–15 minutes could address an estimated 8,000 ambulatory infusion centres globally, a channel currently served by send-out testing with 24–48 hour turnaround.

### Multiplex Panel Economics

Bundling CEA with CA 19-9, CA 125 and AFP on one draw raises reagent revenue per specimen by roughly 2.4x while reducing phlebotomy overhead. Vendors owning the analyzer capture disproportionate value.

### Emerging-Market Laboratory Networks

India's expanded NPCDCS framework targets diagnostic capability in 750 district hospitals by 2028 [[8]](https://mohfw.gov.in). Similar build-outs across ASEAN and Sub-Saharan Africa represent the largest untapped volume pool in the Carcinoembryonic Antigen Market.

### Software and Data Monetisation

Longitudinal result trending, delta-check algorithms and recurrence-risk scoring are being sold as subscription modules attached to analyzer contracts. Recurring software revenue carries gross margins near 70%, well above consumables, and locks customers in beyond the hardware refresh cycle.

### Companion Diagnostic Partnerships

[Pharmaceutical](https://www.marketresearchfuture.com/reports/pharmaceutical-market-67551) developers running trials in gastrointestinal oncology increasingly co-develop monitoring protocols with assay vendors. CEA tumor marker testing embedded in trial endpoints creates a validated downstream commercial channel once therapies reach approval.

## Future Outlook

## Carcinoembryonic Antigen Market Future Outlook

### Algorithmic Result Interpretation

Machine-learning delta-check systems that flag clinically meaningful rises against a patient's own baseline are entering routine use. Early deployments at three European academic centres reduced unnecessary imaging referrals by 19% [[19]](https://degruyter.com), shifting vendor differentiation from analytical sensitivity toward interpretive software layered on top of the Carcinoembryonic Antigen Market.

### Platform Economics and Lock-In

Closed-cartridge architectures now account for roughly 68% of new mid-volume analyzer placements. Once installed, switching costs run USD 180,000–450,000 per site including revalidation and staff retraining, which explains why vendors price instruments aggressively and recover margin across the consumable stream.

### Convergence With Molecular Surveillance

Protein and nucleic-acid monitoring are merging into combined recurrence-risk algorithms rather than competing outright. Trials pairing serial antigen measurement with ctDNA showed 14% higher sensitivity for early recurrence than either alone [[15]](https://ascopubs.org), suggesting complementary rather than substitutive demand within the Carcinoembryonic Antigen Market.

### Sustainability and Reagent Footprint

Laboratory decarbonisation reporting under CSRD now covers most large European diagnostics suppliers [[20]](https://efrag.org). Room-temperature-stable reagent formulations eliminate cold-chain emissions and cut distribution costs by an estimated 11%, giving reformulated products a genuine procurement advantage in tender scoring.

## Segment Insights

## Carcinoembryonic Antigen Market Segmentation

### By Product

Product mix within the Carcinoembryonic Antigen Market tilts firmly toward recurring revenue rather than capital equipment.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Assay Kits | 42.4% share | Recurring per-test consumption |
| Analyzers/Instruments | USD 0.68 Billion | Laboratory automation refresh |
| Consumables & Reagents | 7.71% CAGR | Installed base expansion |

Assay kits dominate because every instrument placement generates years of downstream pull-through; vendors routinely accept negative margin on hardware to secure it. Consumables and reagents grow fastest as analyzer fleets installed during the 2020–2024 automation wave reach peak utilisation, with reagent consumption per instrument rising roughly 8% annually through mid-cycle.

### By Application

Application demand across the Carcinoembryonic Antigen Market concentrates in gastrointestinal oncology.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Colorectal Cancer | 40.9% share | Post-resection surveillance protocols |
| Pancreatic Cancer | USD 0.35 Billion | Multiplex panel inclusion |
| Lung Cancer | 17.8% share | Adenocarcinoma monitoring |
| Breast Cancer | 6.9% CAGR | Metastatic disease tracking |
| Liver Cancer | 7.56% CAGR | Rising HCC incidence in Asia |
| Others | 5.4% share | Gastric, ovarian, thyroid monitoring |

Colorectal applications anchor the category through guideline-mandated serial testing across a five-year window. Liver cancer accelerates fastest as hepatitis B cohorts in China and Southeast Asia age into surveillance programmes, where the marker is used alongside AFP for suspected metastatic involvement.

### By End User

End-user distribution reflects where oncology surgery and follow-up actually happen.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Surgical Centres | 45.8% share | Inpatient and post-operative testing |
| Diagnostic Laboratories | 7.44% CAGR | Outreach volume consolidation |
| Academic & Research Institutes | USD 0.34 Billion | Trial endpoint measurement |
| Others | 5.4% share | Physician office laboratories |

Hospitals retain the largest slice because resection and immediate post-operative monitoring occur in-house. Independent laboratories grow faster by absorbing outreach volume from smaller hospitals that cannot justify analyzer economics below 60 tests per day, a threshold that keeps shifting upward as instruments get faster.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.9% share | Surveillance protocol automation, IDN consolidation |
| Europe | USD 0.64 Billion | IVDR compliance, organised screening rollout |
| Asia-Pacific | 7.30% CAGR | County hospital capacity, domestic manufacturing |
| South America | USD 0.13 Billion | Public tender procurement, reagent localisation |
| Middle East & Africa | 4.3% share | Oncology centre build-out, referral laboratories |
| Total | USD 2.32 Billion | — |

Regional performance across the Carcinoembryonic Antigen Market tracks screening infrastructure maturity more closely than per-capita income.

### North America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 82.4% of region | NCCN surveillance adherence, CPT 82378 coverage |
| Canada | USD 0.09 Billion | Provincial colorectal screening programmes |
| Mexico | 7.1% CAGR | IMSS oncology infrastructure expansion |

Consolidation defines the US picture. The five largest integrated delivery networks now standardise immunoassay menus across all member hospitals, converting instrument selection into multi-site, seven-year reagent agreements. Canada's provincial programmes, particularly Ontario's ColonCancerCheck, feed steady referral volume into hospital laboratories [[16]](https://england.nhs.uk).

### Europe

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 22.8% of region | Statutory health insurance coverage breadth |
| UK | USD 0.10 Billion | NHS Bowel Cancer Screening Programme |
| France | 6.4% CAGR | Plan Cancer 2021–2030 funding |
| Italy | 11.9% of region | Regional screening harmonisation |
| Spain | USD 0.05 Billion | Autonomous community programme scaling |
| Nordic Countries | 6.7% CAGR | Registry-linked surveillance |
| Russia | 5.8% of region | Federal oncology programme procurement |
| Rest of Europe | USD 0.08 Billion | CEE screening programme launches |

Regulatory pressure reshaped European supply. IVDR reclassified most tumour marker assays into Class C, requiring notified body review; roughly 18% of legacy CE-marked immunoassay products were withdrawn rather than recertified between 2022 and 2024 [[7]](https://health.ec.europa.eu). Surviving portfolios gained share by default.

### Asia-Pacific

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 34.6% of region | Healthy China 2030 county hospital funding |
| India | 8.1% CAGR | NPCDCS district diagnostic expansion |
| Japan | USD 0.12 Billion | Ageing population, gastric cancer surveillance |
| South Korea | 7.6% of region | National Cancer Screening Programme |
| ASEAN | 7.9% CAGR | Private hospital chain investment |
| Rest of Asia-Pacific | USD 0.04 Billion | Referral laboratory networks |

Domestic manufacturers changed the competitive equation here. Mindray, Autobio and Maccura together supply an estimated 41% of Chinese immunoassay analyzer placements, typically at 40–55% below imported list prices [[17]](https://csml.org.cn). Volume-based procurement rounds since 2023 have accelerated that substitution.

### South America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 56.3% of region | SUS oncology network tenders |
| Argentina | USD 0.02 Billion | Provincial hospital procurement |
| Rest of South America | 6.1% CAGR | Private laboratory chain growth |

Brazil's INCA projected 45,600 new colorectal cases annually for the 2023–2025 triennium [[18]](https://inca.gov.br), and public procurement responded with consolidated national tenders. Price remains the dominant award criterion, favouring vendors with local reagent fill-finish operations over premium imported portfolios.

### Middle East & Africa

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.9% of region | Vision 2030 healthcare cluster investment |
| UAE | USD 0.02 Billion | Medical tourism oncology centres |
| South Africa | 6.3% CAGR | NHLS laboratory network modernisation |
| Egypt | 11.4% of region | Presidential cancer initiative screening |
| Rest of MEA | USD 0.03 Billion | Donor-funded diagnostic capacity |

Saudi Arabia's health sector transformation allocated SAR 30 billion toward specialised care clusters through 2030 [[10]](https://vision2030.gov.sa), including six new comprehensive cancer centres. Each requires a full immunoassay menu from commissioning, creating concentrated equipment purchases with long reagent tails.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration sits at the upper end of moderate. Estimated HHI for the Carcinoembryonic Antigen Market falls between 1,150 and 1,350, with the top five suppliers holding roughly 58–64% of global revenue. Regional fragmentation is pronounced: Chinese domestic manufacturers and Indian reagent specialists compete effectively on price in open-tender markets while the multinationals defend closed-platform installed bases in North America and Western Europe.

| Company | Est. Revenue Share Range | Key Offerings for Carcinoembryonic Antigen Market | Strategic Positioning |
| --- | --- | --- | --- |
| Roche Diagnostics | ~17–21% | Elecsys CEA, cobas e analyzer family | Broadest installed base; ECL platform leadership |
| Abbott Laboratories | ~12–15% | ARCHITECT and Alinity i CEA assays | Menu breadth with mid-volume laboratory focus |
| Siemens Healthineers | ~9–12% | ADVIA Centaur, Atellica IM CEA | Workflow integration with imaging portfolio |
| Danaher (Beckman Coulter) | ~8–11% | Access CEA, DxI 9000 immunoassay analyzer | High-throughput core laboratory specialist |
| Thermo Fisher Scientific | ~5–7% | B·R·A·H·M·S and research-use immunoassays | Research and trial-endpoint channel strength |
| Fujirebio (H.U. Group) | ~4–6% | Lumipulse G CEA | Tumour marker menu depth; Japan and EU strength |
| bioMérieux | ~3–5% | VIDAS CEA | Mid-volume and decentralised laboratory niche |
| Sysmex Corporation | ~3–4% | HISCL immunoassay CEA reagents | Asia-Pacific distribution; haematology bundling |
| DiaSorin | ~2–4% | LIAISON CEA | Specialty menu positioning in Europe |
| Bio-Rad Laboratories | ~2–3% | Quality control materials, EQA programmes | Standardisation and QC layer |
| QuidelOrtho | ~2–3% | VITROS immunodiagnostic CEA | Dry-slide chemistry differentiation |
| Randox Laboratories | ~1–3% | Biochip array multiplex panels | Multiplex-first challenger |

## Recent News & Developments

## Recent News & Developments

- Roche Diagnostics (March 2024): Expanded cobas pro integrated solutions availability to 14 additional emerging markets, targeting mid-volume laboratories previously served by semi-automated systems [[3]](https://roche.com).
- European Commission (May 2023): Confirmed EUR 38.5 million in EU4Health grants for colorectal screening pilots in seven member states, widening the diagnosed population entering surveillance [[1]](https://consilium.europa.eu).
- Abbott Laboratories (September 2024): Received CE mark under IVDR for Alinity i tumour marker menu extensions, securing continuity in European hospital tenders through the compliance transition [[4]](https://abbott.com).
- Fujirebio (January 2025): Announced a co-development agreement with a Japanese pharmaceutical developer for gastrointestinal oncology monitoring endpoints, extending the [companion diagnostic](https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077) channel [[21]](https://hugp.com).
- Beckman Coulter Diagnostics (July 2023): Launched DxI 9000 in Asia-Pacific with throughput of 215 tests per hour, aimed directly at high-volume Chinese and Korean reference laboratories [[12]](https://danaher.com).
- National Health Service England (November 2024): Extended bowel screening eligibility to age 50, adding an estimated 1.1 million people to the screening cohort and lifting downstream diagnostic volume [[16]](https://england.nhs.uk).
- Sysmex Corporation (June 2025): Completed acquisition of a regional immunoassay reagent manufacturer in Southeast Asia to localise supply and shorten tender lead times [[22]](https://sysmex.co.jp).
- US FDA (February 2024): Issued updated guidance on analytical validation expectations for tumour marker assays used in surveillance rather than screening contexts, clarifying an ambiguity that had slowed submissions [[11]](https://fda.gov).

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global market for carcinoembryonic antigen assay kits, analyzers, consumables and reagents across clinical and research settings |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 6.68% (2026–2035) |
| Market Size Checkpoints | USD 2.32 Billion (2025); USD 2.47 Billion (2026); USD 4.42 Billion (2035) |
| Fastest Growing Segments | Consumables & Reagents (product); Liver Cancer (application); Diagnostic Laboratories (end user); Asia-Pacific (geography) |
| Companies Profiled | Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher (Beckman Coulter), Thermo Fisher Scientific, Fujirebio, bioMérieux, Sysmex, DiaSorin, Bio-Rad Laboratories, QuidelOrtho, Randox Laboratories |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: What should procurement teams evaluate when consolidating vendors in the Carcinoembryonic Antigen Market?**
A: Weigh analyzer lock-in against reagent pricing over a five-to-seven-year horizon. Closed-platform contracts often bury cost escalation in consumables. Request harmonisation data across instrument generations before signing. [Ref 14]

**Q: How does assay standardisation affect result comparability across laboratories?**
A: Manufacturers calibrate against differing reference preparations, so values can diverge 15–25% between platforms. Keep patients on a single assay throughout surveillance. Switching platforms mid-course requires establishing a fresh baseline. [Ref 14]

**Q: Does liquid biopsy displace demand in the Carcinoembryonic Antigen Market?**
A: Circulating tumour DNA panels complement rather than replace protein markers, largely on cost. A single measurement runs USD 15–40 versus USD 800–3,000 for ctDNA. Most guidelines pair them. [Ref 15]

**Q: What reimbursement nuances shape adoption in the Carcinoembryonic Antigen Market?**
A: US payers reimburse surveillance testing under CPT 82378 at roughly USD 25 per unit, with frequency limits tied to disease staging. Coverage denials cluster around screening-intent claims rather than post-resection monitoring. [Ref 11]

**Q: Which integration challenges slow analyzer deployments in mid-size hospital laboratories?**
A: Middleware compatibility with legacy information systems is the usual bottleneck, adding six to fourteen weeks before go-live. Bidirectional interfacing and delta-check configuration consume vendor engineering time rarely priced into base contracts. [Ref 19]

**Q: Are point-of-care formats commercially viable yet?**
A: Cartridge systems reach adequate sensitivity but cost three to five times more per result than centralised immunoassays. Viability today sits in oncology day-care units where turnaround changes the same-visit clinical decision. [Ref 13]

**Q: What competitive risk should investors in the Carcinoembryonic Antigen Market watch most closely?**
A: Reagent commoditisation. As patents lapse, third-party manufacturers undercut branded kits by 30–45%, compressing margins across the installed base. Incumbents defending share are shifting value into software and service contracts. [Ref 13]


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/carcinoembryonic-antigen-market-772*